病理學與病理生理學 教授
職稱：教授
學科專業：病理學與病理生理學
研究方向：
團隊專注于1）探索癌症病因（為何）和機制（如何）；2）并開展新型診療靶點靶标的轉化研究和研發。1）目前靶向藥物的靶點主要是癌基因突變，但相當多的腫瘤患者并不能從中獲益。我們提出“突變非依賴腫瘤”假說，并發現“RNA異常剪接”是環境和腫瘤之間的一種“橋梁”機制，并證實剪接産物“嵌合RNA”和“嵌合蛋白”在腫瘤演化中起驅動作用。基于上述新的機制，我們建立了一系列相應的平台（外泌體平台、嵌合抗體、雙特異抗體等），開展了新型治療靶點和早篩早診靶标的轉化研究和研發，包括外泌體液體活檢早篩早診和外泌體腫瘤疫苗等，并開展了多項臨床試驗；2）針對酪氨酸磷酸酶(PTPs)（抑癌基因）不能成藥的瓶頸，發現PTPs在腫瘤耐藥和化療腦中的新機制，并建立RNA激活平台，研發工程化外泌體抗體導向RNA激活藥物解決PTPs不能成藥的困境。
行政職務：腫瘤精準醫學和病理研究所所長、教育部腫瘤分子生物學重點實驗室副主任
電子郵箱：haozhang@jnu.edu.cn
個人介紹：
張灏教授，太阳集团app首页醫學院教授、博士生導師、博士後指導教授、腫瘤精準醫學和病理研究所所長、教育部腫瘤分子生物學重點實驗室副主任，Annals of Medicine（Taylor & Francis出版社）腫瘤學主編。專注我國高發惡性腫瘤的診治的轉化研究和應用，1）發現RNA異常剪接及其産物（嵌合RNA和嵌合蛋白）作為“突變非依賴腫瘤”驅動機制，并以此為診斷靶标和治療靶點開展了外泌體液體活檢和免疫治療，包括無創性唾液外泌體檢測、基于嵌合RNA的外泌體疫苗；2）酪氨酸磷酸酶(PTPs)抑癌基因在腫瘤中的調控機制和治療靶點，克服PTPs不能成藥的瓶頸研發外泌體包裹的抗體導向RNA激活藥物。近年來以通訊作者發表學術成果，包括PNAS（兩篇）、Clin Cancer Research （兩篇）、Gastroenterology、Mol Cancer、Oncogene（兩篇）、JCI insight、Drug Resistant Update、J Pathology等。獲批十餘項發明專利，榮獲2021年《廣東省科技進步獎二等獎》、2019年及2024年獲得《廣東省醫學科技獎二等獎》、2023年《河南省科技進步一等獎》、2021年《中國産學研合作創新獎》、2021年《金博獎全球高層人才科技創新大賽金獎》、2021年《全國十佳消化道領域臨床研究金獎》、2023年《中國研究型醫院學會醫學研究創新獎一等獎》、《Wiley中國開放科學高貢獻獎》、《2022中國生物醫藥企業最具創新力50強獎》等。擔任中國抗癌協會腫瘤标志專業委員會外泌體技術專家委員會（CSEMV）主委，《外泌體研究轉化和臨床應用專家共識》專家組組長。Cancer Letters（Elsevier 出版社）編委，Extracellular Vesicles & Circulating Nucleic Acids（OAE 出版社）編委，Extracellular Vesicle （Elsevier出版社）編委，Scientific Report（Nature出版社）編委。中國抗癌協會腫瘤标志專業委員會常務委員，中國抗癌協會腫瘤标志物專業委員會常委，中國抗癌協會腫瘤代謝委員會常委，中國臨床腫瘤協會胰腺癌專家委員會常委，亞太醫學生物免疫學會腫瘤學分會副主委，廣東省抗癌協會腫瘤代謝委員會副主委，廣東省抗癌協會腫瘤标志物專業委員會副主委, 廣東省抗癌協會抗腫瘤藥物專業委員會副主委。
1.1994-1999，日本島根醫科大學，博士，發育生物學/細胞生物學
2.1988-1994，中國醫科大學附屬盛京醫院，住院醫/主治醫/講師，内科内分泌科
3.1984-1987，中國醫科大學，碩士，内科内分泌學
4.1979-1984，中國醫科大學，本科，臨床醫學
1.2018-至今，太阳集团app首页，太阳集团1088vip教授、腫瘤精準醫學和病理研究所所長、教育部腫瘤分子生物學重點實驗室副主任
2.2008-2018，汕頭大學醫學院，教授，附屬腫瘤醫院/腫瘤研究中心
3.2004-2008，美國UT MD Anderson 癌症中心，講師，分子腫瘤學系/遺傳系
4.1999-2004，美國貝勒醫學院，博士後研究員，分子細胞學系
※特邀綜述和社論(*通訊作者)
1.Lin Y#,Wang S#,Bremer E*,Zhang H*.Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low‐dose metformin. Cancer Commun (Lond).2021 Aug;41(8):637-641.（EDITORIAL）
2.Wang S#,Lin Y#,Tang H,Cai S,Qiu X,Pan Y,Zhang H*. Exosome-based liquid biopsy: Opportunities and challenges for changing patient care of gastrointestinal cancers.Esophageal Cancer.2023(01):59-73.
3.Chang L#,Ni J#,Zhu Y,Pang B,Graham P,Zhang H*,Li Y*.Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics.2019 May 31;9(14):4130-4140.
4.Zheng L#,Wang L#,Gan J,Zhang H*.RNA activation:promise as a new weapon against cancer. Cancer lett. 2014 Dec 1;355(1):18-24.
5.Ning Z,Gan J,Chen C,Zhang D,Zhang H*.Molecular functions and significance of the MTA family in hormone-independent cancer.Cancer Metastasis Rev. 2014 Dec;33(4):901-919.
6.Su J,Concilla A,Zhang D,Zhao F,Shen F,Zhang H*,Zhou F*.PIWI-interacting RNAs:Mitochondria-based Biogenesis and Functions in Cancer.Genes Dis. 2020 Oct 5;8(5):603-622.
7.Dong X, Bai X, Ni J, Zhang H, Duan W, Graham P, Li Y*.Exosomes and breast cancer drug resistance. Cell Death Dis. 2020 Nov 17;11(11):987.
8.Chu YL,Li H,Ng PLA,Kong ST,Zhang H,Lin Y,Tai WCS,Yu ACS,Yim AKY,Tsang HF,Cho WCS,Wong SCC*.The potential of circulating exosomal RNA biomarkers in cancer.Expert Rev Mol Diagn. 2020 Jul;20(7):665-678.
9.Ma L,Yao Z,Deng W,Zhang D,Zhang H*.The Many Faces of MTA3 Protein in Normal Development and Cancers.Curr Protein Pept Sci. 2016, 17(8): 726-734.
10.Du L#,Ning Z#,Zhang H*,Liu F*.Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.
Chin J Cancer. 2017,36(1):28.
11.Yang Z,Zhang H,Kumar R*.Regulation of E-cadherin. Breast Cancer Online. 2005, 8(03): e15. (Cambridge Univeristy Press, www. camridge. org).
12.Yu Zhou#,Zhimeng Yao,Yusheng Lin,Hao Zhang.From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.Pharmaceutics.2024 Jul 1;16(7):888.
13.Yuhua Meng#,Zhimeng Yao#,Xiurong Ke#,Mengyuan Hu,Hongzheng Ren,Shegan Gao*,Hao Zhang*.Extracellular vesicles-based vaccines:emerging immunotherapies against cancer.Journal of Controlled Release.(已接收）
14.林宇晟, 甘進鋒, 江钰琛, 王飛寒, 張灏*: 外泌體标志物和腫瘤液體活檢的研究進展及現狀。中國癌症防治雜志, 2019, 11(02): 99-103.
15.劉情, 鄭琳, 張灏*: 人源性腫瘤組織異種移植(PDX)模型的研究進展。轉化醫學雜志, 2014, 10. 3969, 2095-3097.
16.黃裔騰, 殷秀凱, 鐘雪雲, 張灏*: 食管鱗癌模式動物的研究進展。世界華人消化雜志, 2011, 19(16): 1704-1710.
17.李宗泰, 張灏*: 外周血遊離DNA甲基化檢測: 食管鱗癌早期診療的新機遇。轉化醫學雜志, 2012, 1(1)：45-48.
18.李金平, 甯志豐, 劉複興, 張灏*: 老藥新用, 小分子藥物二甲雙胍的抗腫瘤研究進展。中國生化藥物雜志, 2016 , 36 (8) : 16-21
19.王姝宏，餘幼林，李凱，林宇晟，甘進鋒，謝飛淩，李勇，黃思铨，張灏*.外泌體在腫瘤和極端條件中的作用和檢測。中國癌症防治雜志, 2020, 12(3)：239-243.
20.吳曉，楊海軍，高社幹，周福有，張灏*. 原發性食管小細胞癌的研究及診療現狀。食管疾病，2020, 2(1), 8-12.
※專家共識和指南
1.張灏等.《外泌體研究、轉化和臨床應用專家共識》，轉化醫學雜志，2018。
2.張灏等.《CSCO胰腺癌指南2024》
※論著摘選(*通訊作者)
學術論文(*通訊作者)
1.Li K#,Lin Y,Luo Y,Xiong X,Wang L,Durante K,Li J,Zhou F,Guo Y,Chen S,Chen Y,Zhang D,Yeung SJ,Zhang H*.A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study.Mol Cancer.2022 Jan 18;21(1):21.
2.Li K#,Lin Y#,Zhou Y,Xiong X,Wang L,Li J,Zhou F,Guo Y,Chen S,Chen Y, Tang H,Qiu X,Cai S,Zhang D,Bremer E,Jim Yeung SC, Zhang H*.Salivary extracellular miRNAs for early detection and prognostication of esophageal cancer: a clinical study.Gastroenterology.2023 Oct;165(4):932-945.e9.
3.Xiong X#,Ke X#,Wang L,Lin Y,Wang S,Yao Z,Li K,Luo Y,Liu F,Pan Y, Yeung SC,Helfrich W,Zhang H*.Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles. J Extracell Vesicles. 2022 Aug;11(8):e12243.
4.Wang L#,Lin Y#,Yao Z#,Babu N,Lin W,Chen C,Du L,Cai S,Pan Y,Xiong X,Ye Q, Ren H,Zhang D,Chen Y,Yeung SJ,Bremer E,Zhang H*.Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases.Drug Resist Updat. 2024 Sep;76:101118.2024.101118.
5.Lin Y#,Dong H#,Deng W#,Lin W,Li K,Xiong X,Guo Y,Zhou F,Ma C,Chen Y,Ren H,Yang H,Dai N,Ma L,Meltzer SJ,Yeung SJ,Zhang H*.Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma. Clin Cancer Res. 2019 May 15;25(10):3035-3045.
6.Xiong X#,Ke X#,Wang L#,Yao Z,Guo Y,Zhang X,Chen Y,Pang CP,Schally AV*,Zhang H*.Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proc Natl Acad Sci USA, 2020, 117(12): 6726-6732.
7.Wang S#,Lin Y#,Xiong X,Wang L,Guo Y,Chen Y,Chen S,Wang G,Lin P,Chen H,Yeung SJ*,Bremer E,Zhang H*.Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer. Clin Cancer Res.2020 Sep 15;26(18):4921-4932.
8.Wang L#,Du L,Xiao X,Lin Y,Zhu J,Yao Z,Wang S,Guo Y,Chen Y,
Geary K,Pan Y,Zhou F,Gao S,Zhang D,Yeung SC,Zhang H*.Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.Oncogene.2021 Mar;40(11):1974-1987.
9.Dong H#,Lin W#,Du L#,Yao Z,Li F,Chen S,Huang Y,Ren H,Luo Y,Cai S, Chen Y, Tang H,Qiu X,Pan Y,Huang X,Zhang D,Gao S*,Yeung SJ*,Zhang H*.PTPRO suppresses lymph node metastasis of esophageal carcinoma by dephosphorylating MET.Cancer letters.2023 Jul 28:567:216283.
10.Dong H#,Ma L#,Gan J,Lin W,Chen C,Yao Z,Du L,Zheng L,Ke C,Huang X,Song H,Kumar R,Yeung SC*,Zhang H*.PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. Oncogene. 2017 Jan 19;36(3):410-422.
11.Yao Z#,Dong H#,Zhu J#,Du L#,Luo Y#,Liu Q,Liu S,Lin Y,Wang L,Wang S,Wei W,Zhang K,Huang Q,Yu X,Zhao W,Xu H,Qiu X,Pan Y,Huang X,Yeung SC,Zhang D,Zhang H*.Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment. JCI Insight.2023 Jul 24;8(14):e166306.
12.Luo Y#,Du L#,Yao Z,Liu F,Li K,Li F,Zhu J,Coppes RP,Zhang D,Pan Y, Gao S*,Zhang H*.Generation and Application of Inducible Chimeric RNA ASTN2-PAPPAas Knockin Mouse Model.Cells.2022 Jan 14;11(2):277.
13.Yao Z#, Du L#, Xu M, Li K, Guo H, Ye G,Zhang D,Coppes RP, Zhang H*. MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma. Front Oncol. 2019 Aug 27;9:816.
14.Gan J#,Ke X#,Jiang J#,Dong H#, Yao Z,Lin Y,Lin W,Wu X,Yan S, Zhuang Y,Chu WK,Cai R,Zhang X,Cheung HS,Block NL,Pang CP,Schally AV, Zhang H*. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.Proc Natl Acad Sci U S A.2016 Dec 20;113(51):14745-14750.
15.Dong H#,Xu J,Li W,Gan J,Lin W,Ke J,Jiang J,Du L,Chen Y,Zhong X, Zhang D,Yeung SC,Li X,Zhang H*.Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis. J Pathol. 2017 Mar;241(4):448-462.
16.Dong H#,Du L#,Cai S#,Lin W#,Chen C,Still M,Yao Z,Coppes RP,Pan Y, Zhang D,Gao S*,Zhang H*.Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance. Frontiers in Pharmacology.2022 Apr 1;13:838171.
17.Zhu J#,Wang L#,Liu F,Pan J,Yao Z,Lin Y,Yang Y,Xiong X,Li K,Yang Y, Zhang Y,Chu X,Pan Y*,Zhang H*.Targeting PELP1 Attenuates Angiogenesis and Enhances Chemotherapy Efficiency in Colorectal Cancer.Cancers (Basel).2022 Jan 13;14(2):383.
18.Huang J#,Liu D#,Li J,Xu J,Dong S*,Zhang H*.A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.Annals of medicine.2023;55(2):2260387.
19.Ploeg E#,Ke X#,Britsch I,Hendriks M,Van der Zant F,Kruijff S,Samplonius D,Zhang H*,Helfrich W*.Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.Cancer Letters.2021 Aug 28:521:109-118.
20.Dong H, Xie C, Jiang Y, Li K, Lin Y, Pang X, Xiong X, Zheng J, Ke X, Chen Y, Li Y, Zhang H*. Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration. Front Cell Dev Biol. 2021 Sep 28;9:703537.
21.Wang L#,Xiong X,Yao Z,Zhu J,Lin Y,Lin W,Li K,Xu X,Guo Y,Chen Y, Pan Y,Zhou F,Fan J,Chen Y,Gao S*,Sai-Ching Jim Yeung,Zhang H*. Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer. Cancer Letters. 2021 Mar 31;501:1-11.
22.Feiling Xie#,Hongmei Dong*,Hao Zhang*.Regulatory Functions of Protein Tyrosine Phosphatase Receptor Type O in Immune Cells.Frontiers in immunology.Front Immunol.2021 Nov 22:12:783370.
23.Zou X#,Lin Y#,Ren H#,Meng Y,Chen S,Jiang Y,Cui W,Gu Y,Guo L, Yi L,Zhang D, Zhang H*,Wu G*.PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma. Anticancer Res. 2024,44(2):593-604.
24.Cao S#,Wang X#,Liu X,Li J,Duan L,Gao Z,Lun S,Zhu Y,Yang H,Zhang H*,Zhou F*.Integrative Analysis of Angiogenesis-Related Long Non-Coding RNA and Identification of a Six-DEARlncRNA Signature Associated with Prognosis and Therapeutic Response in Esophageal Squamous Cell Carcinoma. Cancers.2022 Aug 30;14(17):4195.
25.Liu S#,Yang P#,Wang L#,Zou X,Zhang D,Chen W,Hu C,Xiao D,Ren H*,Zhang H*,Cai S*.Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress.Cell Death Discov.2024, 10(1):36.
26.Xingli Dong#,Yusheng Lin#,Kai Li,Gaofeng Liang,Xiaoyi Huang,Jingxuan Pan, Lu Wang,Dongmei Zhang, Tingjiao Liu, Tong Wang, Xiaomei Yan, Long Zhang, Xiaowu Li, Xiujuan Qu, Da Jia,Yong Li* and Hao Zhang*.Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine.Clin Chem Lab Med.2024 Jun 19.Clin Chem Lab Med.2024 Jun 19.
27.Ploeg EM#,Ke X#,Britsch I,Hendriks MAJM,Van der Zant FA,Kruijff S, Samplonius DF,Zhang H*,Helfrich W*.Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles.Cancer Lett. 2021 Aug 28;521:109-118.
28.Du L#,Wang L#,Gan J#,Yao Z,Lin W,Li J,Guo Y,Chen Y,Zhou F*,Jim Yeung SC,Coppes RP,Zhang D,Zhang H*.MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis.iScience.2019 Dec 20;22:353-368.
29.Xu B, Jiang X,Xiong J, Lan J,Tian Y,Zhong L,Wang X,Xu N,Cao H, Zhang W,Zhang H, Hong X, Zhan YY*,Zhang Y*,Hu T*. Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as the RXRα Activator to Inhibit Colon Cancer. J Med Chem. 2020 Jun 11;63(11):5841-5855.
30.Jinfeng Gan, Hao Zhang*.PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.Transl Cancer Res.2020;9(8):4800-4810
31.Dong H#,Xie C#,Yao Z#,Zhao R#,Lin Y,Luo Y,Chen S,Qin Y,Chen Y*, Zhang H*.PTPRO-related CD8 + T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer. Front Immunol.2022 Aug 8:13:947841.
32.Bhagelu R.Achyut,Zhang H*,Kartik Angara,Nahid F.Mivechi,Ali S. Arbab,Lan Ko*.Oncoprotein GT198 Vaccination Delays Tumor Growth in MMTV-PyMT Mice. Cancer Lett. 2020, 476:57-66.
33.Achyut BR,Zhang H,Angara K,Mivechi NF,Arbab AS,Ko L. Achyut BR, Zhang H,Angara K,Mivechi NF, Arbab AS, Ko L. Oncoprotein GT198 vaccination delays tumor growth in MMTV-PyMT mice. Cancer Lett. 2020 Apr 28;476:57-66.
34.Ke X, Xiong X, Lin Y, Zhang H*.Chimeric RNA and Exosomes-Based Liquid Biopsy. Methods Mol Biol.2020;2079:211-218.
35.Tamiya H#,Kim H#,Klymenko O,Kim H*,Feng Y,Zhang T,Han JY,Murao A,Snipas SJ,Jilaveanu L,Brown K,Kluger H,Zhang H,Iwai K,Ronai ZA*.SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. J Clin Invest.2018 Jan 2;128(1):517-530.
36.Wang W#,Lim KG#,Feng M,Bao Y,Lee PL,Cai Y,Chen Y,Zhang H, Marzese D,Hoon DSB,Yu Q*.KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer. Mol Cancer Ther.2018 Sep;17(9):1973-1983.
37.Wang L,Li K,Lin X,Yao Z,Wang S,Xiong X,Ning Z,Wang J,Xu X,Jiang Y,Liu D,Chen Y,Zhang D,Zhang H*.Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.Cancer Lett.2019 May 28;450:22-31.
38.Feng Y#,Ke C#,Tang Q#,Dong H,Zheng X,Lin W,Ke J,Huang J,Yeung SC,Zhang H*.Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis.2014 Feb 27;5(2):e1088.
39.Li Z#,Zou X#,Xie L,Chen H,Chen Y,Yeung SC,Zhang H*.Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.Int J Cancer.2015 Apr 1;136(7):1636-45.
40.Zhang H*,Lin W,Kannan K,uo L,Li J,Chao PW,Wang Y,Chen YP,Gu J,Yen L*.Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma. Oncotarget.2013 Nov;4(11):2135-43.
41.Yu J#,Lin Y#,Xiong X#,Li K,Yao Z,Dong H,Jiang Z,Yu D,Yeung SJ,Zhang H*.Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis. Front Genet.2019 Mar 14;10:202.
42.Wang L,Li W,Li K,Guo Y,Liu D,Yao Z,Lin X,Li S,Jiang Z,Liu Q,Jiang Y, Zhang B,Chen L,Zhou F,Ren H,Lin D,Zhang D,Yeung SJ,Zhang H*.The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma. Cancer Med. 2018 Oct;7(10):5205-5216.
43.Tang Q,Li G,Wei X,Zhang J,Chiu JF,Hasenmayer D,Zhang D,Zhang H*. Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma. Cancer Lett. 2013 Aug 19;336(2):325-37.
44.You Y,Chen Y,Zheng X,Meltzer SJ,Zhang H*.Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett. 2012 Feb 28;315(2):138-44.
45.Zhang S,Zeng D,Peng Y,Yang Y,Zhuang X,Li Z,Wang M,Chen L,Zhang H*.Cancer-related fatigue and chemotherapy-associated adverse effects: correlation with TNF-α, IL-1 and 17-hydroxycorticosteroids.Future Oncol. 2014;10(9):1619-26.
46.Zhang H,Singh RR,Talukder AH,Kumar R*.Metastatic tumor antigen is a direct corepressor of the Wnt4 pathway.Genes Dev.2006 Nov 1;20(21):2943-8.
47.Zhang H,Kuang SQ,Liao L,Zhou S,Xu J*.Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Cancer Res. 2004 Oct 1;64(19):7169-77.
48.Zhang H,Stephens LC,Kumar R*.Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006 Mar 1;12(5):1479-86.
49.Zhou C*,Wu Y,Chen G,Liu X,Zhu Y,Lu S,Feng J,He J,Han B,Wang J, Jiang G, Hu C,Zhang H,Cheng G,Song X,Lu Y,Pan H,Zheng W,Yin AY. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204.
50.Kumar R*,Zhang H,Holm C,Vadlamudi RK,Landberg G,Rayala SK*. Extranuclear coactivator signaling confers insensitivity to tamoxifen.Clin Cancer Res.2009 Jun 15;15(12):4123-30.
51.Peng M,Zhang H,Jaafar L,Risinger JI,Huang S,Mivechi NF,Ko L*. Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97.
52.Tong Z#,Li M#,Wang W,Mo P,Yu L,Liu K,Ren W,Li W,Zhang H,Xu J, Yu C*.Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/beta-Catenin Signaling. J Biol Chem. 2015 Jul 24;290(30):18596-608.
53.Chu WK,Law KS,Chan SO,Yam JC,Chen LJ,Zhang H,Cheung HS, Block NL,Schally AV*,Pang CP*.Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.Proc Natl Acad Sci USA.2016 Dec 13;113(50):14396-14401.
54.Klionsky DJ, Zhang H et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016, 12(1): 1-222.
55.Chen T,Chen Q,Xu Y,Zhou Q,Zhu J,Zhang H,Wu Q,Xu J,Yu C*.SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.JHepatol.2012 Jan;56(1):210-7.
56.Lin Y#, Choukrani G#, Dubbel L, Rockstein L, Freile JA, Qi Y, Wiersma V, Zhang H, Koch KW, Ammatuna E, Schuringa JJ, van Meerten T, Huls G, Bremer E*. VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.Exp Hematol Oncol. 2024 Mar 29;13(1):35.
57.Ploeg EM*,Samplonius DF,Xiong X,Ke X, Hendriks M,Britsch I,van Wijngaarden AP,Zhang H,Helfrich W*.Bispecific antib ody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.J Immunother Cancer.2023 Sep;11(9):e006837.
1.《腫瘤急症治療例析》《人民衛生出版社》主編，2023年；
2.《腫瘤标志物》《人民衛生出版社》編委，2022年；
3.《Chimeric RNA: Methods and Protocols》《Springer出版社》編委；
4.《乳腺癌》《人民衛生出版社》副主編，2019年；
5.《細胞外囊泡》《科學出版社》編委，2019年；
6.《Extracellular Vesicles: From Bench to Bedside》編委；
7.《腫瘤标志物通訊》（外泌體專刊）《中國抗癌協會出版》主編，2018年;
8.《Encyclopedia of Cancer 》(癌症百科全書）《Springer出版社》編委，2002年
1.牙龈卟啉單胞菌誘發微生态失衡促進食管癌發生發展的機制及應用，河南省科學技術進步獎，一等獎，2023年；
2.食管癌腫瘤标志物及液體活檢的應用與開發，廣東省科技廳，廣東省科學技術科技進步獎，二等獎，2020年；
3.牙龈卟啉單胞菌促進食管癌發生發展病因的闡明及應用,中華醫學會,中華醫學科學技術獎三等獎,2023年；
4.液體活檢和老藥新用診治食管癌新機制，新靶點和轉化研究，廣東省醫學會，廣東省醫學會科技進步獎，二等獎，2024年；
5.食管癌早期診斷和治療新方法的轉化研究，廣東省醫學會，廣東省醫學會科技進步獎，二等獎，2019年；
6.低劑量二甲雙胍重編程食管癌免疫微環境：II期臨床研究，Gastroenterology Report,《中華胃腸外科雜志》《中華炎性腸病雜志》聯合頒發, 2020年度十佳消化道領域臨床研究金獎,2020年；
7.中國産學研合作創新與促進獎，中國産學研合作促進會,2021年；
8.上消化道腫瘤診斷和治療新方法的轉化研究，汕頭市科學技術獎勵，一等獎，2018年；
9.食管癌化療敏感性标志物和診療新方法的研究及應用，廣東省藥學會醫院藥學科學技術獎，一等獎，2020年；
10.食管癌化療敏感性标志物和診療新方法的研究及應用，中國藥學會科學技術獎，三等獎，2020年；
11.藥物基因組學和納米載體在腫瘤藥物治療中的應用及評價，廣東省優秀科技成果，2019年；
12.《金博獎全球高層人才科技創新大賽金獎》，2021年；
13.《中國研究型醫院學會醫學研究創新獎一等獎》2022年；
14.《Wiley中國開放科學高貢獻獎》2022年；
15.《2022中國生物醫藥企業最具創新力50強獎》2022年；
指導團隊青年成員獲得過如下項目:
1. 2020年第三屆粵港澳大灣區醫學與健康發展論壇獲得一等獎
2. 2020年太阳集团app首页生命科學創新獎獲得二等獎
3. 2021年第四屆粵港澳大灣區醫學與健康發展論壇獲得二等獎
4. 2021年太阳集团app首页生命科學創新獎獲得二等獎
5. 2023年太阳集团app首页第四屆“全國大學生基礎醫學創新研究暨實驗設計論壇”中榮獲臨床醫學賽道實驗設計組三等獎
6. 2024年太阳集团app首页第五屆基礎醫學創新研究暨實驗設計競賽三等獎
7. 2024年榮獲第二屆廣東省高校實驗室安全知識校際邀請賽微視頻校内選拔賽二等獎
8. 2024年太阳集团app首页第十二屆“挑戰杯”大學生創業計劃競賽“獲得銀獎
1.中國抗癌協會腫瘤标志專業委員會外泌體技術專家委員會（CSEMV）主委
2.《外泌體研究轉化和臨床應用專家共識》專家組組長
3.Annals of Medicine（Taylor & Francis 出版社）腫瘤學主編
4.Cancer Letters（Elsevier 出版社）和Scientific Report（Nature出版社）編委
5.Extracellular Vesicles & Circulating Nucleic Acids&Extracellular Vesicle & 編委
6.Cancer Research，Clinical Cancer Research,Gastroenterology & Journal of Controlled Release & Journal of Pathology & Journal of Extracellular Vesicles & Oncogene & PNAS等雜志的審稿專家
7.《胰腺癌診治指南》撰寫組專家
8.中國抗癌協會腫瘤标志專業委員會常務委員
9.中國抗癌協會腫瘤标志物專業委員會常委
10.中國抗癌協會腫瘤代謝委員會常委
11.中國臨床腫瘤協會胰腺癌專家委員會常委
12.亞太醫學生物免疫學會腫瘤學分會副主委
13.廣東省抗癌協會腫瘤代謝委員會副主委
14.廣東省抗癌協會腫瘤标志物專業委員會副主委
15.廣東省抗癌協會抗腫瘤藥物專業委員會副主委
